Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066766 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2247328 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL17003745 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2016841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9808756 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345161 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL4300294 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9055251 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL136430 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL440982 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043343-A | Nucleic acid vaccine for mutant coronaviruses | 苏州艾博生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230136088-A1 | miRNA-193a for Promoting Immunogenic Cell Death | INTERNA TECHNOLOGIES B.V. (NL) | 2023-05-04 | — | — | US | disclosed |
| EP-4110917-A1 | MIRNA-193A FOR PROMOTING IMMUNOGENIC CELL DEATH | InteRNA Technologies B.V. (NL) | 2023-01-04 | — | — | EP | disclosed |
| US-20220275368-A1 | NEW TREATMENTS INVOLVING MIRNA-193A | INTERNA TECHNOLOGIES B.V. (NL) | 2022-09-01 | — | — | US | disclosed |
| EP-4013869-A1 | NEW TREATMENTS INVOLVING MIRNA-193A | InteRNA Technologies B.V. (NL) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021028081-A1 | NEW TREATMENTS INVOLVING MIRNA-193A | INTERNA TECHNOLOGIES B.V. (NL) | 2021-02-18 | — | — | WO | disclosed |
| US-20210038732-A1 | ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF | INTERNA TECHNOLOGIES B.V. (NL) | 2021-02-11 | — | — | US | disclosed |
| EP-3752164-A1 | ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF | InteRNA Technologies B.V. (NL) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019155094-A1 | ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF | INTERNA TECHNOLOGIES B.V. (NL) | 2019-08-15 | — | — | WO | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991007167-A1 | PROTEIN KINASE ACTIVATORS AS ENHANCERS OF MELANIN PRODUCTION | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038732-A1 | ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF | PLIN3, PLIN5, SREBF2 | FAAH 3449/4885CES1 1016/4885CES2 4189/4885 |
| US-20230136088-A1 | miRNA-193a for Promoting Immunogenic Cell Death | PDCD1, BAD, PDCD1LG2 | FAAH 4465/4885CES1 3896/4885CES2 4745/4885 |
| US-20220275368-A1 | NEW TREATMENTS INVOLVING MIRNA-193A | EYA3, EYA2, PPP3CA | FAAH 4693/4885CES1 3853/4885CES2 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.